Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The Role of Microglial-Mediated Synaptic Loss in Degenerative Cervical Myelopathy
FY 2020-21
Summary
Degenerative cervical myelopathy (DCM) is an umbrella term that encompasses several age-related degenerative conditions that cause a compression of the cervical spinal cord. DCM is the most common cause of spinal cord injury (SCI) and is associated with debilitating functional deficits such as impaired upper limb function. This condition is prevalent in adults over the age of 65, which causes a burden for our increasingly ageing global population. Recent research in a traumatic animal model of SCI has shown that deletion of the fractalkine receptor (CX3CR1) is associated with improved upper limb function and increased synapse formation. The CX3CR1 receptor is a part of the fractalkine signalling pathway (CX3CR1-CX3CL1), which can regulate synaptic pruning in the central nervous system. However, the relationship between fractalkine-mediated synaptic loss and impaired upper limb function in a non-traumatic model of SCI (e.g. DCM) is not well-understood. Based on past research, I hypothesize that the forelimb deficits observed after DCM are in part due to fractalkine-mediated synaptic loss. Either Cx3cr1 or Cx3cl1 deletion should increase the number of synaptic connections and improve functional outcomes. The proposed study aims to: 1) determine the effects of Cx3cr1 and Cx3cl1 deletion on synaptic plasticity and forelimb function following DCM, and 2) examine if re-introduction of CX3CL1 (the fractalkine ligand) via viral vectors will exacerbate deficits. This study is the first to investigate the relationship between fractalkine-mediated synaptic loss and forelimb function in the context of DCM and will reveal novel therapeutic targets for this increasingly prevalent and devastating condition.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449737
Name
Zhou Cindy M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Microglial-Mediated Synaptic Loss in Degenerative Cervical Myelopathy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cx3cl1; Cx3cr1; Degenerative Cervical Myelopathy; Forelimb Dysfunction; Fractalkine Signalling; Microglia; Neuroinflammation; Neuroplasticity; Spinal Cord Injury; Synaptic Loss
Abstract
Degenerative cervical myelopathy (DCM) is an umbrella term that encompasses several age-related degenerative conditions that cause a compression of the cervical spinal cord. DCM is the most common cause of spinal cord injury (SCI) and is associated with debilitating functional deficits such as impaired upper limb function. This condition is prevalent in adults over the age of 65, which causes a burden for our increasingly ageing global population. Recent research in a traumatic animal model of SCI has shown that deletion of the fractalkine receptor (CX3CR1) is associated with improved upper limb function and increased synapse formation. The CX3CR1 receptor is a part of the fractalkine signalling pathway (CX3CR1-CX3CL1), which can regulate synaptic pruning in the central nervous system. However, the relationship between fractalkine-mediated synaptic loss and impaired upper limb function in a non-traumatic model of SCI (e.g. DCM) is not well-understood. Based on past research, I hypothesize that the forelimb deficits observed after DCM are in part due to fractalkine-mediated synaptic loss. Either Cx3cr1 or Cx3cl1 deletion should increase the number of synaptic connections and improve functional outcomes. The proposed study aims to: 1) determine the effects of Cx3cr1 and Cx3cl1 deletion on synaptic plasticity and forelimb function following DCM, and 2) examine if re-introduction of CX3CL1 (the fractalkine ligand) via viral vectors will exacerbate deficits. This study is the first to investigate the relationship between fractalkine-mediated synaptic loss and forelimb function in the context of DCM and will reveal novel therapeutic targets for this increasingly prevalent and devastating condition.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhou, Cindy M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~